Header cover image

South Korean (KOSPI) Healthcare Sector Analysis

UpdatedJan 29, 2023
DataAggregated Company Financials
Companies342
  • 7D1.9%
  • 3M-0.9%
  • 1Y-10.3%
  • YTD1.9%

Over the last 7 days, the Healthcare industry has risen 1.9%, driven by gains in Samsung BiologicsLtd and Celltrion of 1.1% and 2.6%, respectively. In the past year, the industry is down 10%. As for the next few years, earnings are expected to grow by 19% per annum.

Sector Valuation and Performance

Has the South Korean Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 30 Jan 2023₩207.7t₩57.8t₩4.6t16.8x45.1x3.6x
Wed, 28 Dec 2022₩208.9t₩58.0t₩4.4t16.1x47.9x3.6x
Fri, 25 Nov 2022₩213.3t₩57.0t₩4.1t15.6x51.4x3.7x
Sun, 23 Oct 2022₩194.5t₩55.7t₩4.1t14.7x47.7x3.5x
Tue, 20 Sep 2022₩203.1t₩54.8t₩3.8t17.6x53.6x3.7x
Thu, 18 Aug 2022₩232.2t₩54.2t₩3.9t21.2x60.3x4.3x
Sat, 16 Jul 2022₩223.3t₩54.2t₩3.9t20.2x57.5x4.1x
Mon, 13 Jun 2022₩220.4t₩54.2t₩3.9t21.9x56.4x4.1x
Wed, 11 May 2022₩216.1t₩51.1t₩3.9t21.3x55.7x4.2x
Fri, 08 Apr 2022₩228.0t₩51.0t₩4.0t22.7x56.9x4.5x
Sun, 06 Mar 2022₩225.7t₩49.2t₩4.3t21.6x51.9x4.6x
Tue, 01 Feb 2022₩216.9t₩49.0t₩4.3t20.4x50.2x4.4x
Thu, 30 Dec 2021₩263.0t₩49.0t₩4.3t23.8x60.9x5.4x
Sat, 27 Nov 2021₩262.0t₩48.5t₩4.4t22.8x59.2x5.4x
Mon, 25 Oct 2021₩268.1t₩48.0t₩4.3t22.3x62.9x5.6x
Wed, 22 Sep 2021₩305.4t₩48.2t₩4.3t26.4x71.4x6.3x
Fri, 20 Aug 2021₩304.7t₩49.5t₩4.3t27.5x71.2x6.2x
Fri, 04 Jun 2021₩276.3t₩44.3t₩2.9t27.4x95.6x6.2x
Mon, 08 Mar 2021₩255.2t₩42.7t₩2.2t26.6x115.9x6x
Thu, 10 Dec 2020₩274.2t₩41.2t₩1.5t31.9x179.6x6.7x
Wed, 02 Sep 2020₩262.4t₩39.3t₩1.0t38.3x251.5x6.7x
Sat, 06 Jun 2020₩179.8t₩37.7t₩855.3b27.5x210.2x4.8x
Tue, 10 Mar 2020₩137.0t₩36.6t₩803.2b24.4x170.6x3.7x
Price to Earnings Ratio

174.8x


Total Market Cap: ₩140.4tTotal Earnings: ₩803.2bTotal Revenue: ₩36.6tTotal Market Cap vs Earnings and Revenue0%0%0%
South Korean Healthcare Sector Price to Earnings3Y Average 106.8x202120222023
Current Industry PE
  • Investors are pessimistic on the South Korean Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 45.1x which is lower than its 3-year average PE of 107x.
  • The 3-year average PS ratio of 5.1x is higher than the industry's current PS ratio of 3.6x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 79% per year over the last three years.
  • Revenues for these companies have grown 16% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the South Korean Healthcare sector?

KR Market3.72%
Healthcare1.93%
Healthtech10.75%
Medical Equipment3.68%
Biotech2.17%
Healthcare Services1.83%
Pharma1.41%
Life Sciences1.16%
Industry PE
  • Investors are most optimistic about the Life Sciences industry even though it's trading below its 3-year average PE ratio of 190x.
    • Analysts are expecting annual earnings growth of 19.0%, which is higher than its past year's earnings growth of 15.8% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 33% over the next 5 years.
  • This is better than its past earnings growth rate of 24% per year.
  • In contrast, the Healthcare Services industry is expected to see its earnings grow by 7.8% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
A207940 Samsung BiologicsLtd₩809.00k1.1%
+₩640.6b
9.5%PE113.5x
A068270 Celltrion₩166.80k2.6%
+₩616.2b
14.9%PE41.5x
A302440 SK bioscienceLtd₩80.30k8.1%
+₩460.7b
-51.3%PE22.1x
A326030 SK Biopharmaceuticals₩76.20k6.3%
+₩352.4b
0.5%PS14.4x
A048260 Osstem Implant₩187.20k15.2%
+₩345.7b
n/aPE51.3x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

A207940

₩809,000.00

Samsung BiologicsLtd

7D

1.1%

1Y

9.5%

A302440

₩80,300.00

SK bioscienceLtd

7D

8.1%

1Y

-51.3%

A069620

₩147,800.00

Daewoong pharmaceuticalLtd

7D

-1.5%

1Y

13.3%

A048260

₩187,200.00

Osstem Implant

7D

15.2%

1Y

n/a

A068270

₩166,800.00

Celltrion

7D

2.6%

1Y

14.9%

A196170

₩35,600.00

ALTEOGEN

7D

4.7%

1Y

-11.0%

A377740

₩8,660.00

BioNote

7D

-3.8%

1Y

n/a

A294090

₩19,990.00

EOFLOWLtd

7D

27.7%

1Y

-10.0%

A214370

₩136,800.00

Caregen

7D

-5.0%

1Y

115.1%

A290650

₩21,950.00

L&C Bio

7D

-3.9%

1Y

-30.5%

A119610

₩29,900.00

Interojo

7D

-6.1%

1Y

11.2%

A091990

₩59,300.00

Celltrion Healthcare

7D

2.1%

1Y

-1.3%

A244460

₩6,160.00

OLIPASS

7D

-13.2%

1Y

-17.4%

A009420

₩15,970.00

Hanall Biopharma

7D

-2.6%

1Y

-8.7%

A003520

₩3,340.00

Yungjin Pharm

7D

-3.0%

1Y

-28.6%